%20(1).webp)
Adult ADHD referrals have grown faster than almost any other area of medicine over the past five years, and the clinicians qualified to assess and treat it have not kept pace. That gap has created a genuine bottleneck: patients waiting months or years for a diagnosis, and doctors who want to help but lack the specific, structured training that ADHD assessment and prescribing now demand.
This guide breaks down what a genuinely strong ADHD training pathway for doctors looks like in 2026: what it should cover, how it should be structured, and how to judge whether a course will actually leave you competent, not just certified. It draws on Global ADHD Network's own course pathway throughout, since it's built specifically around the two skills doctors most often need: accurate diagnosis using validated tools like DIVA-5, and safe, guideline-aligned prescribing once a diagnosis is confirmed.
You'll find direct detail on the Diagnosis Course, the Management Course, and the specialist add-ons that extend a core ADHD qualification into a broader neurodevelopmental practice, covering autism co-occurrence and the specific presentation of ADHD in women.
By the end, you should have a clear framework for evaluating any ADHD course, a realistic sense of what a well-run training day actually involves, and a shortlist of where to start based on your current caseload.
The numbers explain the demand better than anything else. CDC data now puts current ADHD diagnosis among US adults at roughly 6.0%, around 15.5 million people, up sharply from a previous estimate of 4.4%. More than half of adults with a current diagnosis, 55.9%, received it in adulthood rather than childhood, and between 2021 and 2024 more than a million additional adult cases were diagnosed in the US alone, close to 22,000 new cases every month. Meanwhile, 36.5% of adults with ADHD received no treatment at all in the past year, and 71.5% of those prescribed stimulant medication reported difficulty filling their prescriptions due to ongoing shortages.
Behind those figures sits a workforce problem. Diagnosing adult ADHD properly means using a structured interview such as DIVA-5, ruling out overlapping presentations like anxiety, depression, and trauma responses, and applying DSM-5 criteria with real precision rather than a quick checklist. In the UK, the NICE NG87 guideline is explicit that diagnosis should be specialist-led, and many indemnity providers now expect documented training in the specific tools used before they will cover a clinician for independent assessment work. General medical training simply doesn't cover this in depth, which is exactly why dedicated ADHD courses exist and why choosing the right one matters so much.
There's also a career dimension worth naming plainly. Private ADHD assessment and management has become one of the more accessible ways for doctors, psychiatrists, and nurse prescribers to build a private practice income stream, precisely because the gap between demand and trained supply is unusually wide. A well-chosen course is not just a learning exercise; it's often the specific qualification that unlocks a new area of clinical work altogether.
The clinical difficulty also deserves more attention than it usually gets in general training. Adult ADHD rarely presents in isolation. Anxiety, low mood, sleep disruption, and a history of childhood trauma can all produce inattention, restlessness, and poor executive function that superficially resembles ADHD, and untangling which symptoms belong to which condition takes real skill. A structured interview like DIVA-5 exists precisely to force that differentiation systematically rather than relying on clinical impression alone, and courses that fail to build genuine fluency with it tend to leave clinicians under-confident in exactly the cases that matter most: adults with overlapping or ambiguous presentations, rather than the straightforward, textbook cases that make up a smaller share of real referrals. This is one of the clearest ways to separate a course that produces a certificate from one that produces a competent assessor.
Before looking at any specific course, it helps to have a consistent checklist, since these are the same questions worth asking about any ADHD training you come across.
Accreditation and guideline alignment. Does the course carry recognised CPD certification, and is the content mapped to a current national guideline, such as NICE NG87 in the UK? A course that hasn't been reviewed against the latest version of the relevant guideline risks certifying clinicians in slightly outdated practice, particularly around first-line medication choices and monitoring intervals, which shift more often than most doctors expect.
Tool-specific competency, not just theory. The strongest courses build hands-on fluency with the actual instruments clinicians will use in clinic. DIVA-5 for adult diagnosis is the clearest example: a course that describes the tool in a slide deck is not the same as one that gives you supervised practice actually administering it.
Audience fit. Is the course genuinely designed for doctors and prescribers, or is it a broader multi-disciplinary course where prescribing-specific content is thin? A course built for a mixed audience of doctors, nurses, psychologists, and pharmacists can still work well for doctors, provided the prescribing and diagnostic depth doesn't get diluted for the sake of breadth.
Format and time commitment. Single-day intensives suit clinicians fitting training around existing caseloads. Longer, multi-module programmes suit those wanting a slower, more gradual build, but require a bigger upfront commitment of protected time.
Cost relative to depth. Price alone tells you very little. What matters is whether the depth of training, the amount of supervised practice, and the CPD hours awarded justify the fee for your specific goals.
Independent reviews. Testimonials from clinicians in comparable roles are a far more reliable signal than marketing copy. Global ADHD Network, for instance, publishes more than 1,150 course reviews from doctors, nurses, psychologists, and pharmacists who have completed its training, which is worth reading in full before committing to any course, this one included.
With that framework in mind, here's a detailed look at what a well-built ADHD training pathway actually covers, starting with the skill most doctors need first.
The ADHD Assessor Training / Diagnosis Course is built to take a doctor, nurse, psychologist, or pharmacist from general clinical knowledge to practical competence in diagnosing adult ADHD using evidence-based methods. It's delivered as a single full-day remote session, has been completed by more than 1,150 clinicians, and starts from £795.
The curriculum covers five core areas. Understanding ADHD builds a working grasp of how the condition presents and the functional impact it has across work, relationships, and daily life. Diagnostic criteria training applies DSM-5 criteria alongside validated screening tools, giving clinicians a structured way to move from initial suspicion to a defensible clinical decision. DIVA-5 assessment training is the centrepiece: DIVA, the Diagnostic Interview for ADHD in Adults, is one of the most widely recognised structured interview tools available, and the course builds genuine fluency in administering it rather than simply describing its structure. Historical and current perspectives trace how understanding of ADHD has evolved, helping clinicians place current best practice in context rather than treating today's guidelines as fixed and self-evident. Finally, case studies and interactive breakout sessions let participants apply diagnostic reasoning to realistic scenarios with peer discussion, rather than absorbing the material passively.
For any clinician planning to take on ADHD assessment work, whether inside the NHS or in private practice, this is typically the natural starting point, not least because indemnity providers increasingly expect documented DIVA-5 competency before covering assessment work at all. It's also worth noting that DIVA-5 fluency built here transfers directly into the co-occurring autism assessment work covered later in this guide, since a solid grounding in structured diagnostic interviewing makes ADI-R training considerably more straightforward.
Diagnosis and ongoing management require distinctly different skills, which is why the ADHD Prescribing and Management Course exists as a separate, complementary programme. It focuses on the practical realities of treating adults with ADHD once a diagnosis is confirmed, priced from £1,200 for doctors and £1,500 for consultants and psychiatrists.
Medication management is the first pillar, covering stimulant and non-stimulant options, their mechanisms, and appropriate titration strategies, closely mirroring NICE guidance, which positions agents like lisdexamfetamine and methylphenidate as first-line choices with defined starting and maximum doses. Non-pharmacological interventions, including CBT, coaching strategies, and psychoeducation, form the second pillar, recognising that medication alone rarely resolves the full functional impact of the condition. Long-term management covers ongoing monitoring, side-effect management, and treatment adjustment, in line with NICE's recommendation of six-monthly reviews including blood pressure, pulse, and weight checks. Legal and ethical considerations address the specific regulatory scrutiny that comes with prescribing controlled stimulant medication, an area where oversight has tightened as prescription volumes have risen. Applied case studies close out the course, giving participants a chance to work through realistic prescribing and adjustment decisions rather than memorising dosing tables in the abstract.
Combined, the Diagnosis and Management courses make up what Global ADHD Network calls the ADHD Specialist Certification pathway, a combination increasingly recognised as fulfilling the standard NICE expects of practitioners qualified to both diagnose and treat ADHD independently, and together they carry up to 16 CPD-certified hours. For a doctor building a genuine end-to-end ADHD service, rather than handling only one half of the pathway and referring patients elsewhere for the rest, completing both courses is generally the more coherent and more patient-friendly route.
ADHD and autism frequently co-occur, and clinicians building a neurodevelopmental caseload rarely stay confined to one condition for long. The ADI-R Training Course builds fluency in the structured parent and caregiver interview across all three algorithm domains, social interaction, communication, and restricted or repetitive behaviours, and trains clinicians to interpret scores against both DSM-5 and ICD-11 thresholds. It also covers integrating ADI-R findings within a wider multi-modal assessment battery alongside ADOS-2, reflecting how autism diagnosis is rarely made from a single instrument in current practice.
For clinicians wanting observation-based competency specifically, the ADOS-2 Specialist Certification covers the semi-structured, standardised observational assessment that complements interview tools like ADI-R, with a heavier emphasis on supervised practice and inter-rater reliability than most single-day CPD courses. Because ADOS-2 depends on consistent, standardised observation of communication and social behaviour, the training leans more heavily on repeated practice and feedback than on lecture content, which is exactly what inter-rater reliability requires in real clinical use.
Holding certification across ADHD, ADI-R, and ADOS-2 meaningfully widens the referral types a doctor can accept without redirecting patients elsewhere for a second assessment pathway, and it means a single clinician, rather than a chain of separate specialists, can manage a patient's full neurodevelopmental assessment from first referral through to a confirmed diagnosis.
Beyond the individual ADI-R and ADOS-2 certifications, Global ADHD Network runs a dedicated Co-Occurring Autism and ADHD Course that addresses a specific, and surprisingly common, clinical problem: patients whose presentation plausibly fits either condition, or both at once.
This scenario comes up more often in adult referrals than many clinicians initially expect, partly because certain features, difficulty with social communication, rigid routines, and sensory sensitivities, can look similar across both conditions, and partly because the two genuinely do co-occur at meaningfully elevated rates. The course works through the differential and combined diagnostic challenges this creates, building a structured approach to deciding when a patient needs one diagnosis, both, or further assessment before either can be confirmed. For clinicians who have already built diagnostic and prescribing competency through the core ADHD pathway, this course is a natural next step toward genuine specialist status in adult neurodevelopmental assessment.
ADHD in women has historically been significantly under-diagnosed, largely because early diagnostic criteria were built around hyperactive presentations more typical in boys, while inattentive presentations, more common in girls and women, were frequently missed or misattributed to anxiety or mood disorders. The ADHD in Women course is built directly around closing that gap.
It covers how presentation differs from the more commonly recognised male-typical pattern, how hormonal fluctuations across the menstrual cycle, perimenopause, and menopause can mask or worsen symptoms, and how masking behaviours, a well-documented coping pattern where women consciously or unconsciously hide symptoms to meet social expectations, can delay diagnosis by years or even decades. Given how much of the recent surge in adult diagnoses is occurring in women identified later in life, this is a comparatively short but genuinely high-value add-on for any clinician who has already completed the core Diagnosis and Management pathway. Clinicians who skip this add-on often find themselves under-recognising ADHD in exactly the patient group where the current diagnostic backlog is growing fastest.
It's worth walking through what a single-day course, the format most doctors end up choosing, actually involves in practice, since the structure matters far more than the length of the course description on a website.
A well-run diagnosis-focused day typically opens with a grounding section on the condition itself: prevalence, functional impact, and how presentation differs across childhood, adolescence, and adulthood, before moving into the diagnostic criteria proper. This is where DSM-5 criteria get applied directly to case vignettes rather than simply read aloud, and where validated screening tools are introduced as the entry point into a fuller assessment rather than the assessment itself.
The middle of the day is usually where the real value sits: structured, supervised practice with the DIVA-5 interview itself. Rather than watching a demonstration once, participants in a strong course work through sections of the interview in pairs or small groups, ask questions about ambiguous answers, and get feedback on how to probe further when a patient's account is vague or contradictory, which happens more often in real clinics than in tidy training vignettes. Global ADHD Network's Diagnosis Course builds this in through interactive breakout sessions specifically, which is a meaningful point of difference from lecture-only formats that leave participants to figure out the interview's practical rhythm on their own after the course ends.
The afternoon typically shifts toward differential diagnosis and case complexity: working through scenarios where anxiety, depression, or trauma histories complicate the clinical picture, and discussing how to document reasoning defensibly, since a diagnosis that later faces scrutiny needs a clear paper trail showing how alternative explanations were considered and ruled out. A management-focused course follows a similar day-long arc, moving from medication mechanisms and NICE-aligned first-line choices through to monitoring schedules, side-effect management, and the legal and ethical considerations specific to prescribing controlled stimulant medication, again closing with applied case studies rather than pure theory.
Knowing this structure in advance helps you judge whether any ADHD course you're considering is actually built around applied skill-building or is closer to a recorded lecture with a certificate attached at the end.
Doctors who complete just one course from this list are usually able to handle a narrow slice of ADHD-related referrals well. Doctors who build out a fuller pathway, Diagnosis, Management, and one or both of the co-occurring autism certifications, tend to end up handling a much wider range of referrals without needing to pass patients on elsewhere partway through their care.
A sensible sequencing for most doctors starts with the Diagnosis Course, since assessment is usually the first point of contact with a new patient. The Management Course follows naturally once a clinician is comfortable diagnosing and ready to take on prescribing responsibility directly, rather than referring every confirmed diagnosis to a separate prescriber. From there, the ADHD in Women course is a fast, high-value addition given how much of the current diagnostic backlog sits in that population specifically. Finally, ADI-R, ADOS-2, and the Co-Occurring Autism and ADHD Course round out a genuinely comprehensive neurodevelopmental practice for clinicians who want to handle autism and ADHD referrals under one roof.
Not every doctor needs the full pathway. A GP wanting to screen and refer more accurately may only need the Diagnosis Course. A psychiatrist already running a busy ADHD prescribing service may only need the Management Course and the Women's add-on. The point isn't to complete every course available, it's to map your training deliberately onto the referrals you actually see, or want to start seeing, rather than picking courses at random.
A few recurring mistakes show up again and again among doctors picking their first ADHD course, and most are avoidable once you know to look for them.
Choosing on price alone. The cheapest option is sometimes the right one, but a course priced well below comparable programmes has often cut hands-on practice time, DIVA-5 supervised sessions in particular, to keep costs down. Ask specifically how much of the course time is applied practice versus lecture before comparing fees.
Assuming any CPD certificate satisfies indemnity requirements. Indemnity providers increasingly want to see training tied to a named, validated instrument rather than a generic certificate of attendance. Confirm with your specific insurer what they expect before assuming a course qualifies you for independent assessment work.
Skipping the management side after completing diagnosis training. Some clinicians complete a diagnosis course, start assessing patients, and only later realise they need separate, dedicated training to prescribe and monitor treatment safely. Planning for both from the outset avoids a gap in service that patients often notice and dislike, having to be referred elsewhere mid-pathway for prescribing.
Overlooking co-occurring conditions. Autism and ADHD overlap often enough that a diagnosis-only skill set leaves many referrals only partially resolved. Clinicians who build in ADI-R or ADOS-2 competency early tend to need fewer external referrals later, which matters both for patient continuity and for the efficiency of a private practice.
Not checking course currency against the latest guidelines. ADHD guidance has shifted meaningfully in recent years, particularly around first-line stimulant choices and monitoring intervals. A course that hasn't been updated to reflect the current version of NICE NG87 risks certifying clinicians in slightly outdated practice.
Three practical questions tend to settle the decision faster than comparing course descriptions side by side.
What does your current or intended caseload actually require? A GP starting to accept adult ADHD referrals needs DIVA-5 competency first and foremost, which points squarely at the Diagnosis Course. A psychiatrist already comfortable diagnosing but less confident prescribing stimulants benefits more from the Management Course.
How much protected time do you realistically have? Single-day courses fit around existing clinical commitments far more easily than multi-module programmes. Be honest about what you can actually commit to without training becoming a source of burnout rather than growth.
Does the certification unlock something concrete? If the goal is starting to see private ADHD patients within a defined indemnity framework, a combined Diagnosis and Management pathway is a faster, more defensible route than assembling less formal CE credits from several disconnected sources.
If you're unsure which combination fits your situation, Global ADHD Network explicitly invites enquiries from clinicians deciding between courses, which is worth using before committing to the higher-cost Management or combined Specialist Certification pathway.
For UK doctors, every course choice sits inside the broader GMC revalidation framework. The GMC requires continuing professional development every year, tailored to actual scope of practice and reviewed at annual appraisal, with most royal colleges recommending around 50 CPD credits per year, roughly 250 across a five-year cycle. A course chosen because it's convenient rather than genuinely relevant to your practice is weaker evidence at appraisal than one that clearly maps to a defined area of clinical work, which is one reason Global ADHD Network states its CPD hour allocation upfront, up to 16 hours across the combined Diagnosis and Management pathway.
Indemnity is the other practical consideration. Medical defence organisations increasingly ask specific questions about documented training before confirming or extending cover for ADHD assessment and prescribing work, particularly around structured tools like DIVA-5. A generic CPD certificate carries less weight here than one tied to a named, validated instrument, which is exactly why tool-specific training, DIVA-5, ADI-R, and ADOS-2 competency in particular, matters more for indemnity purposes than broader, less specific CPD activity.
Whichever course you choose, confirm directly with your specific indemnity provider what documentation they expect before you rely on any single certificate to open up new clinical work. Keeping a clear record of course content, CPD hours awarded, and the specific tools covered makes that conversation considerably easier when it comes up at appraisal or renewal.
The gap between patient demand and trained clinicians has made ADHD assessment one of the stronger private-practice opportunities currently available to doctors, particularly compared with more saturated specialty areas. Clinicians who complete a combined diagnosis and management pathway frequently move into private ADHD clinics, either independently or through networks connecting certified clinicians with patients, an option Global ADHD Network supports directly through its own referrals network and careers board.
Certified clinicians tend to see the fastest return on course fees wherever the gap between diagnosed demand and available specialist capacity is widest, both in how quickly they can begin seeing relevant patients and in the fee levels those assessments can reasonably command in private practice. Given how much of the recent rise in adult diagnoses is happening in previously underserved groups, women in particular, clinicians who pair core ADHD certification with a targeted add-on like the ADHD in Women course are often well placed to meet demand that many general services still aren't set up to handle well.
It's worth being realistic about the ramp-up period too. Most newly certified clinicians don't fill a private ADHD caseload overnight; building a steady referral flow typically takes several months of networking, word-of-mouth, and, in many cases, a listing on a referral network or careers board aimed specifically at ADHD-trained clinicians. Doctors who treat certification as the first step in a longer practice-building process, rather than an instant income switch, tend to have a more accurate picture of what the first year of ADHD-focused private work actually looks like. Where a course provider also offers a referral network, as Global ADHD Network does, that can meaningfully shorten the gap between finishing training and seeing your first patients, since it connects newly certified clinicians directly with people actively searching for assessment and treatment.
Do I need to already work in psychiatry to take an ADHD diagnosis or management course?No. Global ADHD Network's Diagnosis and Management courses are explicitly designed for a mixed audience of doctors, nurses, psychologists, and pharmacists, reflecting how ADHD assessment and prescribing responsibilities are increasingly shared across these roles.
How long does a typical ADHD training course take to complete?Most dedicated diagnosis and management courses, including Global ADHD Network's, run as a single full-day session, which makes them considerably easier to fit around existing clinical commitments than programmes spread across multiple modules or weeks.
Should I take the Diagnosis Course, the Management Course, or both?Doctors planning to offer full ADHD assessment and treatment services generally need both, since diagnosis and ongoing prescribing management require distinct skill sets. Clinicians only handling one side of the pathway, for example a prescriber working alongside a separate diagnostic service, may only need the Management Course.
Is DIVA-5 training essential, or are other screening tools sufficient?Screening tools like the ASRS are useful for initial triage in primary care, but structured diagnostic interviews like DIVA-5 are what most current guidelines, including NICE NG87, expect for a formal specialist diagnosis. A course that builds genuine DIVA-5 competency, such as Global ADHD Network's Diagnosis Course, is generally the stronger long-term investment.
Do these courses count toward my CPD or revalidation requirements?Yes. Global ADHD Network's courses carry stated CPD hours, up to 16 across the combined Diagnosis and Management pathway, which you can present directly at appraisal alongside a description of the specific clinical skills covered.
Can nurses and pharmacists take the same courses as doctors?Yes. Global ADHD Network's Diagnosis and Management courses are explicitly built for a mixed clinical audience, since assessment and prescribing responsibilities in ADHD services are increasingly shared across doctors, nurse prescribers, and pharmacists rather than held by a single role.
What happens if I only complete the Diagnosis Course and not the Management Course?You'll be equipped to assess and diagnose adult ADHD, but not to independently manage ongoing stimulant prescribing with full confidence in titration, monitoring, and side-effect management. Many clinicians start with diagnosis training, build experience, and add management training once they're ready to take on prescribing responsibilities directly, which is a reasonable sequencing as long as patients aren't left without a clear prescribing pathway in the meantime.
The strongest ADHD training available to doctors right now builds genuine, tool-specific competency rather than surface-level familiarity, and maps clearly onto the guidelines and indemnity expectations doctors are actually held to. Global ADHD Network's combined Diagnosis and Management pathway remains the most direct route for a doctor moving into ADHD assessment and treatment from a standing start, with DIVA-5 competency, NICE-aligned prescribing training, and up to 16 CPD hours built into a single, well-reviewed pathway.
From there, add-ons like ADI-R and ADOS-2 certification, the Co-Occurring Autism and ADHD Course, and the ADHD in Women course let you build a broader, more defensible neurodevelopmental practice as your caseload grows. Whichever pathway you choose, prioritise accreditation you can point to at appraisal, tools you can name specifically to an indemnity provider, and reviews from clinicians whose caseload actually resembles your own.
Sources referenced: NICE Guideline NG87, CDC ADHD data, GMC guidance on CPD.
